The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
The therapeutic potential of monoamine oxidase inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683 · cited 1×
“As elevated ROS production has been proposed to be a causative agent in several neurodegenerative disease”
BackgroundReactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A
Brunner, H. G., Nelen, M., Breakefield, X. O., Ropers, H. H., & van Oost, B. A. (1993) · Science · doi:10.1126/science.8211186 · Cited by 1,644
Jouvet, M. (1969) · Science · doi:10.1126/science.163.3862.32 · Cited by 1,282
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
MONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206
Neurodegenerative diseases and oxidative stress
Emerit, J., Edeas, M., & Bricaire, F. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2003.11.004 · Cited by 1,031
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002) · Nature Structural Biology · doi:10.1038/nsb732 · Cited by 644
Self-citationMonoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
Youdim, M. B. H., & Bakhle, Y. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706464 · Cited by 643
Self-citationRascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 539
Self-citationDe Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 527
Self-citationDistinct Monoamine Oxidase A and B Populations in Primate Brain
Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., & Abell, C. W. (1985) · Science · doi:10.1126/science.3875898 · Cited by 504
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H., Hars, V., & Marton, J. (1985) · Journal of Neural Transmission · doi:10.1007/bf01245973 · Cited by 436
Self-citationBrain monoamine oxidase A inhibition in cigarette smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R. R., Schlyer, D. J., Zezulkova, I., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14065 · Cited by 423
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
Mapping Human Brain Monoamine Oxidase A and B with11C-Labeled Suicide Inactivators and PET
Fowler, J. S., MacGregor, R. R., Wolf, A. P., Arnett, C. D., Dewey, S. L., Schlyer, D., Christman, D., Logan, J., Smith, M., Sachs, H., et al. (1987) · Science · doi:10.1126/science.3099392 · Cited by 391
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Self-citationCleeter, M. W. J., Cooper, J. M., & Schapira, A. H. V. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09789.x · Cited by 371
Structure and Mechanism of Monoamine Oxidase
Edmondson, D. E., Mattevi, A., Binda, C., Li, M., & Hubalek, F. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364784 · Cited by 368
Self-citationPivotal Role of Mitochondrial Calcium Uptake in Neural Cell Apoptosis and Necrosis
Kruman, I. I., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720529.x · Cited by 355
Uversky, V. N. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0937-z · Cited by 312
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE
Birkmayer, W., Riederer, P., Ambrozi, L., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91940-7 · Cited by 297
Self-citationRescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
Tatton, W. G., & Greenwood, C. E. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300410 · Cited by 272
Mitochondria in cell death: novel targets for neuroprotection and cardioprotection
Mattson, M. P., & Kroemer, G. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00046-7 · Cited by 264
Herraiz, T., & Chaparro, C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.033 · Cited by 258
Increased stress response and β–phenylethylamine in MAOB–deficient mice
Grimsby, J., Toth, M., Chen, K., Kumazawa, T., Klaidman, L., Adams, J. D., Karoum, F., Gal, J., & Shih, J. C. (1997) · Nature Genetics · doi:10.1038/ng1097-206 · Cited by 258
Radical Ideas about Monoamine Oxidase
Silverman, R. B. (1995) · Accounts of Chemical Research · doi:10.1021/ar00056a003 · Cited by 251
Investigation of serotonin-related genes in antidepressant response
Peters, E. J., Slager, S. L., McGrath, P. J., Knowles, J. A., & Hamilton, S. P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001502 · Cited by 233
Saporito, M. S., Thomas, B. A., & Scott, R. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751200.x · Cited by 232
Hubálek, F., Binda, C., Khalil, A., Li, M., Mattevi, A., Castagnoli, N., & Edmondson, D. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500949200 · Cited by 232
Self-citationWadia, J. S., Chalmers-Redman, R. M. E., Ju, W. J. H., Carlile, G. W., Phillips, J. L., Fraser, A. D., & Tatton, W. G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-03-00932.1998 · Cited by 230
O'Carroll, A.-M., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00500765 · Cited by 230
Self-citationBinda, C., Hubálek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D. E., & Mattevi, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031087c · Cited by 214
Self-citationBurke, W. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00090-1 · Cited by 211
Kragten, E., Lalande, I., Zimmermann, K., Roggo, S., Schindler, P., Müller, D., van Oostrum, J., Waldmeier, P., & Fürst, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5821 · Cited by 208
Corticotropin-releasing hormone in depression and post-traumatic stress disorder
Kasckow, J. W., Baker, D., & Geracioti, T. D. (2001) · Peptides · doi:10.1016/s0196-9781(01)00399-0 · Cited by 204
Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors
Ma, J., Yoshimura, M., Yamashita, E., Nakagawa, A., Ito, A., & Tsukihara, T. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.032 · Cited by 200
Monoamine Oxidases: Certainties and Uncertainties
Tipton, K. F., Boyce, S., O'Sullivan, J., Davey, G. P., & Healy, J. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364810 · Cited by 196
Self-citationNeuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members
Weinreb, O., Bar‐Am, O., Amit, T., Chillag‐Talmor, O., & Youdim, M. B. H. (2004) · The FASEB Journal · doi:10.1096/fj.04-1916fje · Cited by 187
Self-citationAshe, P. C., & Berry, M. D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00016-2 · Cited by 186
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Self-citationMonoamine Oxidase Expression During Development and Aging
Nicotra, A. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00095-0 · Cited by 181
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
Prada, M. D., Zürcher, G., Wüthrich, I., & Haefely, W. E. (1988) · PubMed · Cited by 176
Galter, D., Buervenich, S., Carmine, A., Anvret, M., & Olson, L. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.001 · Cited by 170
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170
Maruyama, W., Akao, Y., Youdim, M. B. H., Davis, B. A., & Naoi, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00448.x · Cited by 169
Self-citationAkao, Y., Maruyama, W., Shimizu, S., Yi, H., Nakagawa, Y., Shamoto‐Nagai, M., Youdim, M. B. H., Tsujimoto, Y., & Naoi, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01047.x · Cited by 166
Self-citationGarrick, N. A., & Murphy, D. L. (1980) · Psychopharmacology · doi:10.1007/bf00433804 · Cited by 166
Bar‐Am, O., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · The FASEB Journal · doi:10.1096/fj.05-3794fje · Cited by 165
Self-citationInvestigation of the functional effect of monoamine oxidase polymorphisms in human brain
Balciuniene, J., Emilsson, L., Oreland, L., Pettersson, U., & Jazin, E. (2002) · Human Genetics · doi:10.1007/s00439-001-0652-8 · Cited by 163
Selegiline for Alzheimer's disease
Birks, J., & Flicker, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000442 · Cited by 162
Berlin, I., Saïd, S., Spreux-Varoquaux, O., Launay, J.-M., Olivares, R., Millet, V., Lecrubier, Y., & Puech, A. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90058-6 · Cited by 160
Youdim, M. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00103-7 · Cited by 160
Self-citationMonoamine oxidase inhibitors and the cheese effect
Anderson, M. C. M., Hasan, F., McCrodden, J. M., & Tipton, K. F. (1993) · Neurochemical Research · doi:10.1007/bf00978365 · Cited by 160
Self-citationLenders, J. W. M., Eisenhofer, G., Abeling, N. G. G. M., Berger, W., Murphy, D. L., Konings, C. H., Wagemakers, L. M., Kopin, I. J., Karoum, F., Gennip, A. H., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118492 · Cited by 153
Youdim, M. B. H., & Weinstock, M. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015131516649 · Cited by 150
Self-citationTatton, W. G., Chalmers-Redman, R. M. E., Ju, W., Mammen, M., Carlile, G. W., Pong, A., & Tatton, N. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.753 · Cited by 147
GREEN, A. R., Mitchell, B., Tordoff, A. F. C., & Youdim, M. B. H. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07506.x · Cited by 146
Self-citationInteractions of monoamine oxidase with substrates and inhibitors
Dostert, P., Benedetti, M. S., & Tipton, K. F. (1989) · Medicinal Research Reviews · doi:10.1002/med.2610090104 · Cited by 144
Self-citationMarras, C., McDermott, M., Rochon, P. A., Tanner, C. M., Naglie, G., Rudolph, A., Lang, A. E., & the Parkinson Study Group (2005) · Neurology · doi:10.1212/01.wnl.0000148603.44618.19 · Cited by 143
Huang, W., Chen, Y., Shohami, E., & Weinstock, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00929-7 · Cited by 141
Tatton, W. G., Chalmers-Redman, R. M. E., & Tatton, N. A. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0827-z · Cited by 139
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model
Waibel, S., Reuter, A., Malessa, S., Blaugrund, E., & Ludolph, A. C. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0481-5 · Cited by 134
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type
Oreland, L., & Gottfries, C. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90023-0 · Cited by 129
Conventional and new antidepressant drugs in the elderly
Gareri, P., Falconi, U., Fazio, P. D., & Sarro, G. D. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00050-7 · Cited by 125
Kalaria, R. N., & Harik, S. I. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb00973.x · Cited by 121
Klann, E., & Thiels, E. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00002-0 · Cited by 120
Tadić, A., Rujescu, D., Szegedi, A., Giegling, I., SINGER, P. A., Möller, H. ‐., & Dahmen, N. (2002) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10013 · Cited by 119
Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease
Kennedy, B. P., Ziegler, M. G., Alford, M. F., Hansen, L. A., Thal, L. J., & Masliah, E. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0828-6 · Cited by 116
Platelet Monoamine Oxidase, Personality and Alcoholism: The Rise, Fall and Resurrection
Oreland, L. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00115-3 · Cited by 113
(−)-Deprenyl, A Selective MAO-B Inhibitor, with Apoptotic and Anti-apoptotic Properties
Magyar, K. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00102-5 · Cited by 112
Marzo, A. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.004 · Cited by 111
Bar‐Am, O., Yogev‐Falach, M., Amit, T., Sagi, Y., & Youdim, M. B. H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02425.x · Cited by 109
Self-citation3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells
Lamensdorf, I., Eisenhofer, G., Harvey-White, J. D., Nechushtan, A., Kirk, K. L., & Kopin, I. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02309-x · Cited by 105
Improvement of motor function in early Parkinson disease by safinamide
Stocchi, F., Arnold, G., ONOFRJ, M. C., Kwieciński, H., Szczudlik, A., Thomas, A., Bonuccelli, U., Dijk, A. V., Cattaneo, C., Sala, P. G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000134672.44217.f7 · Cited by 105
Effect of lazabemide on the progression of disability in early Parkinson's disease
Kieburtz (1996) · Annals of Neurology · doi:10.1002/ana.410400116 · Cited by 105
Neuroprotection in Parkinson's disease: Clinical trials
Stocchi, F., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10488 · Cited by 102
The discovery of antidepressants: A winding path
Pletscher, A. (1991) · Cellular and Molecular Life Sciences · doi:10.1007/bf02041242 · Cited by 99
Mytilineou, C., Radcliffe, P. M., Leonardi, E. T. K., Werner, P., & Olanow, C. W. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010033.x · Cited by 95
Kunduzova, O., Bianchi, P., Pizzinat, N., Escourrou, G., Séguélas, M., Parini, A., & Cambon, C. (2002) · The FASEB Journal · doi:10.1096/fj.01-1008fje · Cited by 95
Hubálek, F., Binda, C., Li, M., Herzig, Y., STERLING, J. J., Youdim, M. B. H., Mattevi, A., & Edmondson, D. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0310885 · Cited by 94
Self-citationDopamine induces proteasome inhibition in neural PC12 cell line
Keller, J. N., Huang, F. F., Dimayuga, E. R., & Maragos, W. F. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00412-3 · Cited by 93
Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
Waldmeier, P. C., & Tatton, W. G. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03000-9 · Cited by 89
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., Hayashi, K., & Kuno, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4037 · Cited by 89
Tatton, W. G., Wadia, J. S., Ju, W. Y. H., Chalmers-Redman, R. M. E., & Tatton, N. A. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7494-4_5 · Cited by 86
Low monoamine oxidase B in peripheral organs in smokers
Fowler, J. S., Logan, J., Wang, G., Volkow, N. D., Telang, F., Zhu, W., Franceschi, D., Pappas, N. R., Ferrieri, R. A., Shea, C. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1833106100 · Cited by 86
Cloning, After Cloning, Knock-out Mice, and Physiological Functions of MAO A and B
Shih, J. H. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00112-8 · Cited by 86
Kitazawa, M., Wagner, J. R., Kirby, M. L., Anantharam, V., & Kanthasamy, A. G. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.26 · Cited by 84
Does phenylethylamine act as an endogenous amphetamine in some patients?
Janssen, P. A. J., Leysen, J. E., Megens, A. A. H. P., & Awouters, F. H. L. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001522 · Cited by 84
Striatal Dopamine Metabolism in Monoamine Oxidase B‐Deficient Mice : A Brain Dialysis Study
Fornai, F., Chen, K., Giorgi, F. S., Gesi, M., Alessandri, M., & Shih, J. C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732434.x · Cited by 84
Inoue, H., Castagnoli, K., der Schyf, C. V., Mabic, S., Igarashi, K., & Castagnoli, N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35176-6 · Cited by 82
Mytilineou, C., Leonardi, E. T. K., Radcliffe, P. M., Heinonen, E. H., Han, S.-K., Werner, P., Cohen, G., & Olanow, C. W. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37288-x · Cited by 81
Kitani, K., Minami, C., Isobe, K., Maehara, K., Kanai, S., Ivy, G. O., & Carrillo, M. C. (2002) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00392-x · Cited by 75
Wong, W. K., Ou, X., Chen, K., & Shih, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202844200 · Cited by 75
Sharma, S. K., Carlson, E. C., & Ebadi, M. (2003) · Journal of Neurocytology · doi:10.1023/b:neur.0000011327.23739.1b · Cited by 74
Lange, D. J., Murphy, P. L., Diamond, B. E., Appel, V., Lai, E. C., Younger, D. S., & Appel, S. H. (1998) · Archives of Neurology · doi:10.1001/archneur.55.1.93 · Cited by 73
Effect of MPTP and l ‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain
Thiffault, C., Aumont, N., Quirion, R., & Poirier, J. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062725.x · Cited by 73
Weinstock, M., Gorodetsky, E. K., Poltyrev, T., Gross, A., Sagi, Y., & Youdim, M. B. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00053-8 · Cited by 72
Self-citation(-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush
Buys, Y. M., Trope, G. E., & Tatton, W. G. (1995) · Current Eye Research · doi:10.3109/02713689508999923 · Cited by 71
Bidirectional promoter of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1
Zhu, Q., Chen, K., & Shih, J. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-12-07393.1994 · Cited by 66
A clinical overview of monoamine oxidase inhibitors
Zisook, S. (1985) · Psychosomatics · doi:10.1016/s0033-3182(85)72877-0 · Cited by 64
Neurorescuing effects of the GAPDH ligand CGP 3466B
Waldmeier, P. C., Boulton, A. A., Cools, A. R., et al. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_13 · Cited by 63
Youdim, M. B. H., Maruyama, W., & Naoi, M. (2005) · Drugs of today · doi:10.1358/dot.2005.41.6.893613 · Cited by 62
Self-citationVondriska, T. M., Klein, J. B., & Ping, P. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.4.h1434 · Cited by 62
Family-based case-control study of cigarette smoking and Parkinson disease
Scott, W. K., Zhang, F., Stajich, J. M., Scott, B. L., Stacy, M. A., & Vance, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000150905.93241.b2 · Cited by 61
Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion
Kunduzova, O., Bianchi, P., Parini, A., & Cambon, C. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01913-1 · Cited by 60
A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?
Clarke, C. E. (2004) · Movement Disorders · doi:10.1002/mds.20057 · Cited by 59
The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine.
Hasan, F., McCrodden, J. M., Kennedy, N. P., & Tipton, K. F. (1988) · PubMed · Cited by 59
Self-citationMaruyama, W., Boulton, A. A., Davis, B. A., Dostert, P., & Naoi, M. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170093 · Cited by 58
Dissociating Barrel Development and Lesion-Induced Plasticity in the Mouse Somatosensory Cortex
Rebsam, A., Seif, I., & Gaspar, P. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4191-04.2005 · Cited by 57
PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat
Maj, R., Fariello, R. G., Ukmar, G., Varasi, M., Pevarello, P., McArthur, R. A., & Salvati, P. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00554-8 · Cited by 56
Poltyrev, T., Gorodetsky, E. K., Bejar, C., Schorer-Apelbaum, D., & Weinstock, M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2229-z · Cited by 56
Sagot, Y., Toni, N., Perrelet, D., Lurot, S., King, B., Rixner, H., Mattenberger, L., Waldmeier, P. C., & Kato, A. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703633 · Cited by 56
Burke, W. J. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482913 · Cited by 55
Clinical trials of neuroprotection for Parkinson’s disease
LeWitt, P. A. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s23 · Cited by 54
Monoamine oxidase B inhibitors for early Parkinson's disease
Turnbull, K., Caslake, R., Macleod, A. D., Ives, N. J., Stowe, R. L., & Counsell, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004898.pub2 · Cited by 53
Effects of selegiline (l-deprenyl) during smoking and short-term abstinence
Houtsmuller, E. J., Thornton, J. A., & Stitzer, M. L. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1152-9 · Cited by 53
Edelstein, S. B., & Breakefield, X. O. (1986) · Cellular and Molecular Neurobiology · doi:10.1007/bf00711066 · Cited by 53
Seymour, C. B., Mothersill, C. E., Mooney, R., Moriarty, M. J., & Tipton, K. F. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601361 · Cited by 52
Self-citationQin, F., Shite, J., Mao, W., & Liang, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01306-2 · Cited by 49
Transcription factor AP-2 and monoaminergic functions in the central nervous system
Damberg, M. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0325-1 · Cited by 49
Selegiline Treatment Facilitates Recovery After Stroke
Sivenius, J., Sarasoja, T., Aaltonen, H., Heinonen, E. H., Kilkku, O., & Reinikainen, K. J. (2001) · Neurorehabilitation and neural repair · doi:10.1177/154596830101500305 · Cited by 49
Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation
Berlin, I., Aubin, H., Pedarriosse, A., Rames, A. D., Lazabemide in Smoking Cessation Study Investigators, Lancrenon, S., & Lagrue, G. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00258.x · Cited by 47
Protection from MPTP‐induced neurotoxicity in differentiating mouse N2a neuroblastoma cells
Girolamo, L. A. D., Hargreaves, A. J., & Billett, E. E. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00066.x · Cited by 45
Li, Y., Omori, K., Suzukawa, J., & Inagaki, C. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.032 · Cited by 45
Andr�s, A., Soldevila, M., Navarro, A., Kidd, K., Oliva, B., & Bertranpetit, J. (2004) · Human Genetics · doi:10.1007/s00439-004-1179-6 · Cited by 44
Holt, A. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00104-9 · Cited by 43
Steroid regulation of monoamine oxidase activity in the adrenal medulla
Youdim, M. B. H., Banerjee, D. K., Kelner, K. L., Offutt, L. A., & Pollard, H. B. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.6.2495232 · Cited by 42
Self-citationArai, R., Karasawa, N., Kurokawa, K., Kanai, H., Horiike, K., & Itô, A. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00351-2 · Cited by 40
Le, W., Jankovic, J. J., Xie, W., Kong, R., & Appel, S. H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00170-5 · Cited by 39
(-)Deprenyl (Selegiline): past, present and future.
Knoll, J. (2000) · PubMed · Cited by 39
l-Deprenyl and physostigmine for the treatment of Alzheimer's disease
Marin, D. B., Bierer, L. M., LAWLOR, B. A., Ryan, T. M., Jacobson, R., Schmeidler, J., Mohs, R. C., & Davis, K. L. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02714-8 · Cited by 38
Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research
Yaşar, S., Goldberg, J., & Goldberg, S. R. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7494-4_6 · Cited by 36
Haplotypes of the monoamine oxidase genes and the risk for substance use disorders
Vanyukov, M. M., Maher, B. S., Devlin, B., Tarter, R. E., Kirillova, G. P., Yu, L., & Ferrell, R. E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20105 · Cited by 36
Selegiline as immunostimulant — a novel mechanism of action?
Müller, T., Kuhn, W., Krüger, R., & Przuntek, H. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_33 · Cited by 35
Antioxidant Effect of Phenelzine on MPP+-Induced Cell Viability Loss in Differentiated PC12 Cells
Lee, C. S., Han, E. S., & Lee, W. B. (2003) · Neurochemical Research · doi:10.1023/a:1026119708124 · Cited by 33
Role of the Redox Protein Thioredoxin in Cytoprotective Mechanism Evoked by (-)-Deprenyl
Andoh, T., Chock, P. B., Murphy, D. L., & Chiueh, C. C. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012302 · Cited by 33
Shin, M.-H., Jang, J.-H., & Surh, Y. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.011 · Cited by 33
Nandigama, R. K., Miller, J. R., & Edmondson, D. E. (2001) · Biochemistry · doi:10.1021/bi011113d · Cited by 33
Self-citationBuccafusco, J. J., Terry, A. V., Goren, T., & Blaugrun, E. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00937-5 · Cited by 32
Li, X., Jin, Q., Juorio, A. V., & Boulton, A. A. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13660.x · Cited by 29
Protection of the aged substantia nigra of the rat against oxidative damage by (−)−deprenyl
de la Cruz, C. P., Revilla, E., Steffen, V. M., Rodríguez‐Gómez, J. A., Cano, J., & Machado, A. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15350.x · Cited by 28
Rőszer, T., Jenei, Z., Gáll, T., Nagy, O., Czimmerer, Z., Serfözö, Z., Elekes, K., & Bánfalvi, G. (2003) · Brain Behavior and Evolution · doi:10.1159/000073757 · Cited by 27
Kier, A., Han, J., & Jacobson, L. (2004) · Endocrinology · doi:10.1210/en.2004-0650 · Cited by 27
Cutillas, B., Ambrosio, S., & Unzeta, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00614-6 · Cited by 27
Ontogenesis of Multiple Forms of Monoamine Oxidase in Rat Brain Regions and Liver
Tsang, D., Ho, K., & Wen, H. (1987) · Developmental Neuroscience · doi:10.1159/000112258 · Cited by 26
Florvall, L., Fagervall, I., Ask, A. L., et al. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00161a020 · Cited by 20
Orologas, A. G., Buckman, T. D., & Eiduson, S. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90505-7 · Cited by 12
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Herrman, H., Stewart, D. E., Diaz-Granados, N., Berger, E. L., Jackson, B., & Yuen, T. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600504 · Cited by 1,338
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015) · Cell · doi:10.1016/j.cell.2014.11.047 · Cited by 1,014
Recent progresses in small-molecule enzymatic fluorescent probes for cancer imaging
Liu, H.-W., Chen, L., Xu, C., Li, Z., Zhang, H., Zhang, X.-B., & Tan, W. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00862g · Cited by 948
Metadata
- Authors
- Youdim, M. B. H., Edmondson, D., & Tipton, K. F.
- Venue
- Nature Reviews Neuroscience
- Published
- 2006-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-309
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2024770800
- Cited by
- 1,363
- References
- 153
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.